Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis

Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort

Chasseur, P
Blockmans, D
von Frenckell, C
Nicolas, J-B
Regniers, C
Vandergheynst, F

May 2020

Introduction: The RAVE trial has revolutionized induction treatment of anti-neutrophil cytoplasmic a...

338. Rituximab maintenance therapy in relapsing ANCA-associated vasculitis

Veronika Satrapová1

April 2022

Background/ Objectives: Rituximab (RTX, an anti-CD20 monoclonal antibody) is now used both as an ind...

332. Adding low dose cyclophosphamide to rituximab is associated with sustained remission in ANCA vasculitis patients

332. Adding low dose cyclophosphamide to rituximab is associated with sustained remission in ANCA vasculitis patients

April 2022

Background: Rituximab (RTX) and cyclophosphamide (CYC) are effective remission-induction therapies ...

Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis

McGregor, JulieAnne G.
Hogan, Susan L.
Kotzen, Elizabeth S.
Poulton, Caroline J.
Hu, Yichun
Negrete-Lopez, Roberto
Kidd, Jason M.
Katsanos, Suzanne L.
Bunch, Donna O.
Nachman, Patrick H.
Falk, Ronald J.

January 2015

Rituximab has been used in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) si...

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial

Jones, R.
Furuta, S.
Tervaert, J.
Hauser, T.
Luqmani, R.
Morgan, M.
Peh, C.
Savage, C.
Segelmark, M.
Tesar, V.
van Paassen, P.
Walsh, M.
Westman, K.
Jayne, D.

January 2015

Objectives The RITUXVAS trial reported similar remission induction rates and safety between rituxima...

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis:2-year results of a randomised trial

Jones, Rachel B.
Furuta, Shunsuke
Tervaert, Jan Willem Cohen
Hauser, Thomas
Luqmani, Raashid
Morgan, Matthew D.
Peh, Chen Au
Savage, Caroline O.
Segelmark, Marten
Tesar, Vladimir
van Paassen, Pieter
Walsh, Michael
Westman, Kerstin
Jayne, David R. W.

June 2015

Objectives The RITUXVAS trial reported similar remission induction rates and safety between rituxima...

354. Safety proile of repeat rituximab treatment in ANCA associated vasculitis: a 10-year single centre study

Pek Ghe Tan1

April 2022

Background: Rituximab is a proven effective induction and remission-maintenance treatment in patient...

Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis.

Jones, Rachel B.
Tervaert, Jan Willem Cohen
Hauser, Thomas
Luqmani, Raashid
Morgan, Matthew D.
Peh, Chen Au
Savage, Caroline O.
Segelmark, Marten
Tesar, Vladimir
van Paassen, Pieter
Walsh, Dorothy
Walsh, Michael
Westman, Kerstin
Jayne, David R. W.

July 2010

Background: Cyclophosphamide induction regimens for antineutrophil cytoplasmic antibody (ANCA)-assoc...

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Jones, RB
Tervaert, JW
Hauser, T
Luqmani, R
Morgan, MD
Peh, CA
Savage, CO
Segelmark, M
Tesar, V
van Paassen, P
Walsh, D
Walsh, M
Westman, K
Jayne, DR

July 2010

BACKGROUND: Cyclophosphamide induction regimens for antineutrophil cytoplasmic antibody (ANCA)-assoc...

Induction Therapy in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Renal Involvement: The Nephrologist's Point of View

Maurizio Salvadori
Aris Tsalouchos

July 2018

Renal involvement with rapidly progressive glomerulonephritis is a common manifestation of antineutr...

Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function

McGregor, JulieAnne G.
Negrete-Lopez, Roberto
Poulton, Caroline J.
Kidd, Jason M.
Katsanos, Suzanne L.
Goetz, Lindsey
Hu, Yichun
Nachman, Patrick H.
Falk, Ronald J.
Hogan, Susan L.

January 2015

Disease control in anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) with immu...

Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis

McAdoo, SP
Medjeral-Thomas, N
Gopaluni, S
Tanna, A
Mansfield, N
Galliford, J
Griffith, M
Levy, J
Cairns, TD
Jayne, D
Salama, AD
Pusey, CD

December 2017

Background: Current guidelines advise that rituximab or cyclophosphamide should be used for the trea...

Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients

Charles, Pierre
Néel, Antoine
Tieulié, Nathalie
Hot, Arnaud
Pugnet, Gregory
Decaux, Olivier
Marie, Isabelle
Khellaf, Mehdi
Kahn, Jean-Emmanuel
Karras, Alexandre
Ziza, Jean-Marc
Deligny, Christophe
Tchérakian, Colas
Guillevin, Loïc
Group, French Vasculitis Study

January 2014

International audienceOBJECTIVES: Rituximab has been shown to induce remission of ANCA-associated va...

Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort

Chasseur, P
Blockmans, D
von Frenckell, C
Nicolas, J-B
Regniers, C
Vandergheynst, F

May 2020

Introduction: The RAVE trial has revolutionized induction treatment of anti-neutrophil cytoplasmic a...

338. Rituximab maintenance therapy in relapsing ANCA-associated vasculitis

Veronika Satrapová1

April 2022

Background/ Objectives: Rituximab (RTX, an anti-CD20 monoclonal antibody) is now used both as an ind...

332. Adding low dose cyclophosphamide to rituximab is associated with sustained remission in ANCA vasculitis patients

332. Adding low dose cyclophosphamide to rituximab is associated with sustained remission in ANCA vasculitis patients

April 2022

Background: Rituximab (RTX) and cyclophosphamide (CYC) are effective remission-induction therapies ...

Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis

McGregor, JulieAnne G.
Hogan, Susan L.
Kotzen, Elizabeth S.
Poulton, Caroline J.
Hu, Yichun
Negrete-Lopez, Roberto
Kidd, Jason M.
Katsanos, Suzanne L.
Bunch, Donna O.
Nachman, Patrick H.
Falk, Ronald J.

January 2015

Rituximab has been used in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) si...

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial

Jones, R.
Furuta, S.
Tervaert, J.
Hauser, T.
Luqmani, R.
Morgan, M.
Peh, C.
Savage, C.
Segelmark, M.
Tesar, V.
van Paassen, P.
Walsh, M.
Westman, K.
Jayne, D.

January 2015

Objectives The RITUXVAS trial reported similar remission induction rates and safety between rituxima...

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis:2-year results of a randomised trial

Jones, Rachel B.
Furuta, Shunsuke
Tervaert, Jan Willem Cohen
Hauser, Thomas
Luqmani, Raashid
Morgan, Matthew D.
Peh, Chen Au
Savage, Caroline O.
Segelmark, Marten
Tesar, Vladimir
van Paassen, Pieter
Walsh, Michael
Westman, Kerstin
Jayne, David R. W.

June 2015

Objectives The RITUXVAS trial reported similar remission induction rates and safety between rituxima...

354. Safety proile of repeat rituximab treatment in ANCA associated vasculitis: a 10-year single centre study

Pek Ghe Tan1

April 2022

Background: Rituximab is a proven effective induction and remission-maintenance treatment in patient...

Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis.

Jones, Rachel B.
Tervaert, Jan Willem Cohen
Hauser, Thomas
Luqmani, Raashid
Morgan, Matthew D.
Peh, Chen Au
Savage, Caroline O.
Segelmark, Marten
Tesar, Vladimir
van Paassen, Pieter
Walsh, Dorothy
Walsh, Michael
Westman, Kerstin
Jayne, David R. W.

July 2010

Background: Cyclophosphamide induction regimens for antineutrophil cytoplasmic antibody (ANCA)-assoc...

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Jones, RB
Tervaert, JW
Hauser, T
Luqmani, R
Morgan, MD
Peh, CA
Savage, CO
Segelmark, M
Tesar, V
van Paassen, P
Walsh, D
Walsh, M
Westman, K
Jayne, DR

July 2010

BACKGROUND: Cyclophosphamide induction regimens for antineutrophil cytoplasmic antibody (ANCA)-assoc...

Induction Therapy in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Renal Involvement: The Nephrologist's Point of View

Maurizio Salvadori
Aris Tsalouchos

July 2018

Renal involvement with rapidly progressive glomerulonephritis is a common manifestation of antineutr...

Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function

McGregor, JulieAnne G.
Negrete-Lopez, Roberto
Poulton, Caroline J.
Kidd, Jason M.
Katsanos, Suzanne L.
Goetz, Lindsey
Hu, Yichun
Nachman, Patrick H.
Falk, Ronald J.
Hogan, Susan L.

January 2015

Disease control in anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) with immu...

Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis

McAdoo, SP
Medjeral-Thomas, N
Gopaluni, S
Tanna, A
Mansfield, N
Galliford, J
Griffith, M
Levy, J
Cairns, TD
Jayne, D
Salama, AD
Pusey, CD

December 2017

Background: Current guidelines advise that rituximab or cyclophosphamide should be used for the trea...

Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients

Charles, Pierre
Néel, Antoine
Tieulié, Nathalie
Hot, Arnaud
Pugnet, Gregory
Decaux, Olivier
Marie, Isabelle
Khellaf, Mehdi
Kahn, Jean-Emmanuel
Karras, Alexandre
Ziza, Jean-Marc
Deligny, Christophe
Tchérakian, Colas
Guillevin, Loïc
Group, French Vasculitis Study

January 2014

International audienceOBJECTIVES: Rituximab has been shown to induce remission of ANCA-associated va...

Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort

Chasseur, P
Blockmans, D
von Frenckell, C
Nicolas, J-B
Regniers, C
Vandergheynst, F

May 2020

Introduction: The RAVE trial has revolutionized induction treatment of anti-neutrophil cytoplasmic a...

338. Rituximab maintenance therapy in relapsing ANCA-associated vasculitis

Veronika Satrapová1

April 2022

Background/ Objectives: Rituximab (RTX, an anti-CD20 monoclonal antibody) is now used both as an ind...

332. Adding low dose cyclophosphamide to rituximab is associated with sustained remission in ANCA vasculitis patients

332. Adding low dose cyclophosphamide to rituximab is associated with sustained remission in ANCA vasculitis patients

April 2022

Background: Rituximab (RTX) and cyclophosphamide (CYC) are effective remission-induction therapies ...

Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis

Abstract

Extracted data

Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis

Abstract

Extracted data

Related items

Related items